Related Experiment Video
Updated: Oct 19, 2025
10:00
Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy
Published on: November 8, 2016
8.7K
Expression Analysis of GD2 by Immunohistochemistry in Invasive Breast Carcinoma: Clinical and Pathologic Correlation
Elaine Zhong1, Edi Brogi1, Timothy M D'Alfonso1
1Departments of Pathology.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|September 21, 2021
Summary
Disialoganglioside GD2 (GD2) is expressed in 35% of breast cancers, particularly in low-grade, ER-positive tumors. GD2 positivity did not correlate with patient survival outcomes in this study.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Disialoganglioside GD2 (GD2) is a cell surface antigen found on neuroectodermal tumors.
- GD2 is a target for immunotherapy in certain cancers.
- Expression data for GD2 in breast cancer is limited.
Purpose of the Study:
- To investigate GD2 expression in breast cancer.
- To assess GD2 as a potential biomarker for targeted breast cancer treatment.
Main Methods:
- Analyzed 386 breast carcinomas using immunohistochemistry with the anti-GD2 3F8 monoclonal antibody.
- Correlated GD2 expression with clinicopathologic features and survival outcomes.
Main Results:
- GD2 was expressed in 134 (35%) of breast carcinomas.
- GD2 positivity was significantly associated with specific histologic types, low grade, estrogen receptor positivity, low stage, and multifocality.
- No significant difference in event-free or overall survival was observed between GD2-positive and GD2-negative tumors.
Conclusions:
- GD2 expression is present in a subset of breast cancers and correlates with favorable clinicopathologic features.
- Further evaluation of GD2 using the 3F8 antibody is warranted as a predictive and prognostic biomarker in breast cancer.
